JPRN-jRCTs031180024招募中2 期
Multi-institutional randomized Phase II trial of a treatment of nivolumab combined with image-guided three dimensional beam-convergent and extremely hypofractionated radiotherapy for patients with unresectable or metastatic renal cell carcinoma. - NIVOIGERCC
Onishi Hiroshi0 个研究点目标入组 100 人开始时间: 2018年10月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Primary registration
- •1)Cytologically or histologically confirmed renal cell carcinoma.or clinically judged as renal cell carcinoma. 2)At least two measurable lesions excluding only lung lesions. 3)Radical operation not applicable 4)Favorable risk: Treatment is either cancelled or complete after the initial treatment; no other prioritized chemotherapy can be applied; any applicable chemotherapy is rejected. Intermediate/poor risk: No other prioritized chemotherapy can be applied after the initial treatment; suitable chemotherapy is not applicable for some reason; suitable chemotherapy is rejected by the patient. 5)Immediate Radiotherapy not applicable 6)Men and women aged 20 or more 7)ECOG Performance status of 0-2 8)Judgement by Radiation-oncologist for indication and safely of irradiation 9)Satisfication of the following criteria in the latest labo data within 7 days of the registration:1.WBC=2000 per uL or more,2.Hb=9.0g per dL or more, 3.PLT=50000 per uL or more, 4.Serum Creatinine=3.0mg per dL or less and eGFR 30mL/min or more 5.Total bililubine=1.5mg per dL or less, 6.GOT(AST)=100IU per L or less, 7.GPT(ALT)=100IU per L or less, 8.SpO2=93% or more(room air) 10)Written informed consent after enough explanation
- •Secondary registration
- •Among the primary registered patients with completion of initial treatment protocol, at the evaluation just before the second registration after the first cycle, no observation of interstitial pneumonitis (Grade 2 or more), acute kidney injury (Grade 4 or more), or other fatal toxicities (Grade 3 or more) , according to the NCI-CTCAE v4.0.
排除标准
- •Primary regisration
- •1)Active double cancer(except for some early or cured cancer as followe:carcinoma in situ, mucosal cancer, stage I prostate, breast, or laryngeal cancer) 2)Serious heart disease,uncontrolled diabetes mellitus despite continuing treatment of insulin,cardiac infarction within 6 months before enrollment,uncontrolled hypertension,history of severe infections,watery diarrhea,paresis of intestine,ileus,autoimmune disease,other severe complications 3)Radiographically (chest X-P or CT image) confirmed interstitial pneumonitis or pulmonary fibrosis 4)Severe emphysema, chronic bronchitis, asthma 5)Continuous systemic administration of steroid 6)Severe mental illness 7)women who are or may be pregnant or in lactatoin 8)Unsuitable patients judged by the attending physician or radiation-oncologist(previous irradiation is ignored) 9)A history of pretreatment within 7 days before the start of first Nivolumab
- •Secondary registration
- •1) Tumor progression, or decreasing of the ECOG performance status less than 3
- •2) Principal Investigator will end the protocol, when tumor progression, or significant fatal or life-threatening toxicities were observed.
- •3) Disappearance of the irradiation site.
研究者
相似试验
招募中
2 期
Multi-institutional randomized Phase 2 trial of a treatment of nivolumab combined with stereotactic body radiotherapy for patients with unresectable or metastatic renal cell carcinoma.nresectable or metastatic renal cell carcinomaJPRN-UMIN000030972Department of Radiology, University of Yamanashi100
已完成
不适用
Multi-institutional randomized phase 2 trial of the combination chemotherapy of carboplatin and pemetrexed for advanced nonsquamous non-small-cell lung canceronsquamous non-small-cell lung cancerJPRN-UMIN000008842Kansai Clinical Oncology Group20
已完成
2 期
A multicenter randomized phase II clinical trial with neo -adjuvant chemotherapy containing eribulin mesylate for triple negative primary breast cancer patients (Neo-Entrance study)Patients with operable primary triple-negative breast cancer without prior treatmentJPRN-UMIN000023162Japan Breast Cancer Research Group)100
招募中
2 期
A multicenter phase II randomized trial to evaluate systemic therapy versus systemic therapy in combination with stereotactic radiotherapy in patients with metastatic colorectal cancerBowel cancerrectum cancer1001799010017991colon cancerNL-OMON52282niversitair Medisch Centrum Utrecht105
进行中（未招募）
1 期
A randomized, multi-center phase II trial to assess the efficay of 5-azacytidine added to standard primery therapy in elderly patients with newly diagnosed AML. - AML-AZAThe disease under investigation is newly diagnosed Acute Myeloid Leucemia (AML) in elderly patients.MedDRA version: 13.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-004583-40-DEniversitaetsklinikum Muenster234